Sonu Abraham, MD, FACC
@SonuAbrahamMD
Followers
2K
Following
2K
Media
205
Statuses
735
HF Cardiologist @GillKentucky via @NMCardioVasc, @LaheyHospital, @svhmedres @CalicutCollege | @CircAHA #SoMeEditor | Infiltrative CMs | #HCM | Cardiogenic Shock
Joined July 2019
1/ In this #OriginalResearch paper in @CircAHA from #AHA25, Jiang et al report the findings of the DARE-AF trial that investigated the effect of dapagliflozin on the prevention of early recurrence of AF after catheter ablation Here's a summary🧵 https://t.co/zmHFHhvxU3
1
11
18
0
1
9
4/ Clinical perspective 💡 Coramitug may complement stabilizers & silencers by clearing amyloid deposits. 💡 Biomarker & echo gains suggest cardiac remodeling potential. 💡 Favorable safety supports phase 3 evaluation → Moving from disease stabilization to possible reversal
0
2
2
3/ Key findings ✅ NT-proBNP ↓48% with coramitug 60 mg/kg vs placebo (95% CI −65%, −22%; p=0.0017) ✅ Improved echo parameters → indicating possible amyloid clearance ✅ Well tolerated ⚠️ 6MWT: no significant difference vs placebo #SoMeEditor @CircAHA
1
2
2
2/ Trial design ✅ Phase 2, randomized, double-blind, placebo-controlled (52 wks) ✅ n=104 ATTR-CM pts (median age 77; 84% NYHA II) ✅ 90% on tafamidis or TTR mRNA silencers ✅ Dosing (1:1:1): placebo, coramitug 10 mg/kg, or 60 mg/kg IV q4wk Primary endpts: 6MWT & NTproBNP
1
2
0
🧵1/ Current ATTR amyloidosis therapies: 💡 TTR stabilizers 💡 RNA silencers → Slow new amyloid formation but don’t remove deposits. Coramitug, a mAb to misfolded TTR, aims to clear amyloid. Phase 2 RCT shows benefits. #AHA25 #SimPub @CircAHA 👇 https://t.co/wKll0tqhLk
ahajournals.org
Background: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive disease caused by the deposition of transthyretin as amyloid in the myocardium. Current therapies may slow disease...
1
11
15
4/ 💡 Clinical Implications In HT pts: Alirocumab = safe & powerful LDL-C lowering Short-term plaque impact unclear Possible reasons: low baseline LDL, inflammation-driven CAV, potent statins used Longer follow-up may be required #SoMeEditor @CircAHA
0
3
0
3/ Key Findings LDL-C dropped: 73 → 32 mg/dL 💪 Total cholesterol, ApoB, Lp(a) ↓ No significant effect on: plaque volume, coronary physiology Well-tolerated ✅
1
3
1
2/ 📊 Trial Design 114 HT recipients: 57 alirocumab vs 57 placebo All on rosuvastatin Invasive coronary assessment at baseline & 1 yr: • angiography, NIRS-IVUS • FFR, CFR, IMR Primary endpoint: change in plaque volume #SoMeEditor @CircAHA
1
3
3
Had great fun moderating a session on #GeneticCardiomyopathies at #AHA25 alongside @KhazanieHeart and @vnparikh ! Excellent discussions on #ACM, #HCM and #DCM by @gasperettimd , @CarolynHoMD and @WilsonTangMD !
0
3
13
It was a pleasure moderating an excellent collection of digital posters at #AHA25 on Hopping Heart Failure Science !
1
4
15
Having a great time at #AHA25 with our fellows @universityofky @GillKentucky @LeivaOrly #VasiliKatsadouros
0
4
17
It was a pleasure kicking off a brilliant session discussing the #ShockToolKit in #CardiogenicShock at #AHA25 ! @universityofky @GillKentucky
1
5
28
Excellent session on the #AdipokineHypothesis in #HFpEF at #AHA25 ! Visceral adiposity is key! BMI may not be the way to measure obesity!
0
4
22
Excellent work by @LeivaOrly , our very own Interventional fellow @universityofky @GillKentucky on #PH in patients with myeloproliferative neoplasms at #AHA25 ! #Cardioonc
0
2
13
Cardiogenic shock session being kicked off by @GillKentucky AHFT’s very own @SonuAbrahamMD! @VLSorrellImages
0
2
4
Kicking off #AHA25 with Late Breaking clinical trials focusing on #Cardiometabolic therapeutics! #Triglycerides #SoMeEditor @CircAHA
0
2
11
It was a pleasure to speak about the practical aspects of #GDMT initiation and up-titration in #HF at the annual #FamilyMedicineReview2025. Thank you @UKYFamMed @UKFamilyMed for the invitation! The role of our #PCPs in #HFprevention & care is crucial! 🫀#FunctionNotFailure
0
6
28